1,357
Participants
Start Date
April 16, 2024
Primary Completion Date
September 8, 2025
Study Completion Date
January 22, 2026
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
Participants will receive FF/UMEC/VI
Inhaled corticosteroids/long-acting beta-2 agonists
Participants will receive ICS/LABA
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Quilmes
GSK Investigational Site, Rosario
GSK Investigational Site, Sydney
GSK Investigational Site, Blacktown
GSK Investigational Site, Kanwal
GSK Investigational Site, Coffs Harbour
GSK Investigational Site, Bruce
GSK Investigational Site, Concepción del Uruguay
GSK Investigational Site, Brisbane
GSK Investigational Site, Mendoza
GSK Investigational Site, Osborne Park
GSK Investigational Site, Spearwood
GSK Investigational Site, New Windsor
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Philadelphia
GSK Investigational Site, New Orleans
GSK Investigational Site, Charlotte
GSK Investigational Site, Asheville
GSK Investigational Site, Spartanburg
GSK Investigational Site, Rock Hill
GSK Investigational Site, Tallahassee
GSK Investigational Site, Orlando
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, North Miami Beach
GSK Investigational Site, Miami
GSK Investigational Site, Palm Springs
GSK Investigational Site, Port Charlotte
GSK Investigational Site, Taichung
GSK Investigational Site, Cincinnati
GSK Investigational Site, Warren
GSK Investigational Site, Missoula
GSK Investigational Site, Normal
GSK Investigational Site, Papillion
GSK Investigational Site, Little Rock
GSK Investigational Site, Dallas
GSK Investigational Site, Beaumont
GSK Investigational Site, Newport Beach
GSK Investigational Site, Bangor
GSK Investigational Site, Linwood
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Rosario
GSK Investigational Site, Windsor
GSK Investigational Site, Trois-Rivières
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Gifu
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hyōgo
GSK Investigational Site, Kagawa
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kumamoto
GSK Investigational Site, Matsuyama
GSK Investigational Site, Miyazaki
GSK Investigational Site, Miyazaki
GSK Investigational Site, Nagaoka-Shi
GSK Investigational Site, Niigata
GSK Investigational Site, Okawa-shi
GSK Investigational Site, Ōita
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Yokohama
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
Lead Sponsor
GlaxoSmithKline
INDUSTRY